SCHEMBL3371609

SCHEMBL3371609

CCOC(=O)C(=[N+]=N)C(=O)c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
MAPT P10636 6/20 0.43
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 2/20 0.43
NPC1 O15118 1/20 0.43
MITF O75030 1/20 0.43
RAB9A P51151 1/20 0.43
APP P05067 1/20 0.42
LMNA P02545 2/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 1/20 0.40
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13310387 0.86 CES2 (0.49) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL5479636 0.84 CES2 (0.60) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL14024241 0.81 CES2 (0.53) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL28533131 0.81 CES2 (0.56) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL3127858 0.76 CES2 (0.50) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL3127863 0.76 CES2 (0.50) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL16418302 0.75 MAPT (0.53) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL9333827 0.75 ALDH1A1 (0.49) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL11756323 0.75 ALDH1A1 (0.53) CES2CES1MAPTALDH1A1KDM4E
SCHEMBL2353369 0.74 MAPT (0.49) CES2CES1MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD CES2 587/4885CES1 1511/4885MAPT 3947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.